Top Markets
#1 Black Phoenix Black Phoenix +355.13%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +68.86%
#4 OpenEden OpenEden +60.23%
#5 Akedo Akedo +56.95%
#6 BasedHype BasedHype +26.68%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +19.51%
#9 Humanity Humanity +19.18%
#10 Ether.fi Ether.fi +17.32%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Clasificación en acciones #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Precio por acción
$0.01292666
Última sincronización: 2025-04-08
Capitalización bursátil
$157.54K
Cambio (1 día)
6.84%
Cambio (1 año)
0.00%
País
GB
Comercio Synairgen plc (SNG)

Categoría

Healthcare
Ingresos de Synairgen plc (SNG)
Ingresos en Jun 2024 TTM: 0.00
Según los últimos informes financieros de Synairgen plc, los ingresos actuales de la empresa (TTM) son 0.00. En 2022, la empresa obtuvo unos ingresos de 0.00 igual a los ingresos del año 2021, que fueron de 0.00. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Synairgen plc desde 2004 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 $133.74 -98.03%
2017 $6.79K 0.00%
2016 0.00 -100.00%
2015 $36.84 -99.45%
2014 $6.68K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 $248.65K 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 $156.44K 3.46%
2006 $151.21K -58.23%
2005 $361.99K 143.32%
2004 $148.77K 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE